DAWEX
11.5.2022 08:47:13 CEST | Business Wire | Press release
Dawex , the leading technology company for data exchange, data marketplace and data hub, unveils the MGTS Data Marketplace, the first non-personal data marketplace for the automotive sector (distribution, sales, use, wear and tear, maintenance and equipment), and more globally for individual mobility. The MGTS Data Marketplace aims at bringing together all stakeholders and observers of today's and tomorrow's individual mobility to enable its users to understand, anticipate and innovate in this rapidly changing sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505006017/en/
Present in 18 countries with 2,000 customer contact points under the Midas, Norauto and ATU multi-brand car maintenance banners, Mobivia is the leader in its sector with over 50 million customers per year and 50 years of existence.
"Dawex provided us with the technology solution to monetize and generate value from our data or those of our partners, by creating a Data Exchange Platform that is powerful, efficient, secure and easy to use," explains Ludovic Codeluppi, International Product Leader at MGTS.
The MGTS Data Marketplace leverages Dawex Data Exchange technology to facilitate the collection, centralization, distribution, exchange and monetization of non-personal data in this sector. The different market players keep control over their data, decide with whom to share it and for what purposes, in an environment that guarantees security and traceability. Thanks to Dawex business and regulatory expertise, the MGTS Data Marketplace meets the requirements of European and international regulations, and is perfectly in line with the future Data Act .
"In less than a year, MGTS has built strong relationships with organizations outside of our immediate ecosystem thanks to Dawex introductions," continues Ludovic Codeluppi. "The circulation and commercialization of data between these stakeholders will play a key role in the development of new business models.”
Dawex technology enables MGTS to orchestrate and animate a vast data ecosystem from the automotive and mobility sector. It provides its stakeholders with the means to better understand and improve their user experience, increase productivity and efficiency, and boost innovation. The MGTS deployment is another illustration of Dawex technology leadership, demonstrating the footprint of its solid reference architecture.
"Data exchange has become a fundamental component of business competitiveness and economic sovereignty," comments Fabrice Tocco, Dawex co-CEO. "Organizing the circulation and monetization of its data within its ecosystem is an imperative for all players in the retail sector.”
Sign up to the MGTS Data Marketplace
About Dawex
In today’s economy where data has become a product of unlimited potential, with its own value, and a source of new revenue streams, Dawex technology allows organizations to create new ecosystems around data exchange platforms that meet regulatory requirements and address traceability and security challenges. Dawex is the leading technology company for data exchange , data marketplace and data hub to orchestrate the sourcing, the distribution and the exchange of data. Awarded Technology Pioneer by the World Economic Forum in 2020, Dawex is an active member of Gaia-X . Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505006017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom